Santamaría Martínez, Enrique
Loading...
Email Address
person.page.identifierURI
Birth Date
Job Title
Last Name
Santamaría Martínez
First Name
Enrique
person.page.departamento
Ciencias de la Salud
person.page.instituteName
ORCID
person.page.observainves
person.page.upna
Name
- Publications
- item.page.relationships.isAdvisorOfPublication
- item.page.relationships.isAdvisorTFEOfPublication
- item.page.relationships.isAuthorMDOfPublication
1 results
Search Results
Now showing 1 - 1 of 1
Publication Open Access Fiber-based early diagnosis of venous thromboembolic disease by label-free D-dimer detection(Elsevier, 2019) Zubiate Orzanco, Pablo; Urrutia Azcona, Aitor; Ruiz Zamarreño, Carlos; Egea Urra, Josune; Fernández Irigoyen, Joaquín; Giannetti, Ambra; Baldini, Francesco; Díaz Lucas, Silvia; Matías Maestro, Ignacio; Arregui San Martín, Francisco Javier; Santamaría Martínez, Enrique; Chiavaioli, Francesco; Del Villar, Ignacio; Ingeniaritza Elektrikoa, Elektronikoaren eta Telekomunikazio Ingeniaritzaren; Institute of Smart Cities - ISC; Ingeniería Eléctrica, Electrónica y de Comunicación; Gobierno de Navarra / Nafarroako GobernuaD-dimer is a useful diagnostic biomarker for deep vein thrombosis or pulmonary embolism, collectively referred to as venous thromboembolism (VTE). The ability to detect in real-time the amount of D-dimer with a fast and reliable method is a key step to anticipate the appearance of these diseases. Here, the results of a highly specific and sensitive biosensor for the detection of D-dimer based on lossy mode resonance in fiber optics are presented. The unique features of specialty fibers in light management integrated with microfluidics allow detecting D-dimer in human serum with a detection limit of 100 ng/mL, a value 5-fold below the clinical cutoff value. Comparison of the results achieved with mass-spectrometry-based proteomics, which allows for the identification of beta- and gamma-chains of fibrinogen, demonstrates the ability of our platform to specifically (>90%) recognize D-dimer. Therefore, this technology potentially represents a paradigm shift in the development of a simple, high-specificity and label-free biosensing platform, which can be applied to speed up diagnostic healthcare processes of venous thromboembolism toward an early diagnostic and personalized treatment system.